The USMCA Creates New Barriers, Delays Patient Access to Affordable Medicines — Especially Biosimilars.
The Agreement would delay U.S. patient access to competition from low-cost, high-quality generic and biosimilar medicines, and fails to include strong incentives for their approval and uptake.
Issues